- Conditions
- Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
- Interventions
- No Intervention
- Other
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Palo Alto, California • Sacramento, California + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1873–1896
of 8,158
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dry Eye Syndromes, Keratoconjunctivitis Sicca
- Interventions
- Intranasal Lacrimal Neurostimulator (Oculeve)
- Device
- Lead sponsor
- Oculeve, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Andover, Massachusetts • Memphis, Tennessee
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Fluticasone Propionate/Formoterol Fumarate, Formoterol Fumarate, Placebo
- Drug
- Lead sponsor
- Dey
- Industry
- Eligibility
- 40 Days and older
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Fullerton, California • San Diego, California + 20 more
- Conditions
- Unsafe Sex, IV Drug Usage
- Interventions
- Not listed
- Lead sponsor
- Phoenix Children's Hospital
- Other
- Eligibility
- 13 Years to 24 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Constipation
- Interventions
- Tegaserod and Polyethylene Glycol 3350
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 64 Years · Female only
- Enrollment
- 52 participants
- Timeline
- 2005
- U.S. locations
- 14
- States / cities
- Oro Valley, Arizona • Phoenix, Arizona • Tucson, Arizona + 11 more
- Conditions
- Epilepsy
- Interventions
- Placebo, Brivaracetam, Antiepileptic drugs with market authorization available per country
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 768 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 61
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 52 more
- Conditions
- Type 2 Diabetes
- Interventions
- Bromocriptine mesylate
- Drug
- Lead sponsor
- VeroScience
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Miami, Florida + 2 more
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- Budesonide oral suspension
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 11 Years to 55 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more
- Conditions
- Hypertension, Pulmonary
- Interventions
- Sotatercept 0.3 mg/kg, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Drug
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 46 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Refractory Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Tuvusertib, Ultrasound Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Orange, California • Aventura, Florida + 19 more
- Conditions
- Prostate Carcinoma
- Interventions
- Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Sinecatechins
- Drug · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 21 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 345
- States / cities
- Fairbanks, Alaska • Phoenix, Arizona • Fayetteville, Arkansas + 224 more
- Conditions
- Atopic Dermatitis, Eczema
- Interventions
- Lebrikizumab, Placebo, Topical Corticosteroid (TCS)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more
- Conditions
- Parkinson's Disease
- Interventions
- ND0612
- Drug
- Lead sponsor
- NeuroDerm Ltd.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 23 more
- Conditions
- Cancer
- Interventions
- Calm Meditation Mobile App, Health Education Podcast Mobile App
- Behavioral
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Graft Versus Host Disease, Ocular Surface Disease, oGVHD, Ocular Graft vs Host Disease, Brimonidine Tartrate, Lubricant Eye Drops, Ophthalmic Solutions, Graft vs Host Disease
- Interventions
- Brimonidine Tartrate, Placebos
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 10 more
- Conditions
- Overweight, Obesity
- Interventions
- Semaglutide, Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 17,604 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 205
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Glendale, Arizona + 163 more
- Conditions
- Hereditary Angioedemas
- Interventions
- No intervention
- Other
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Miami, Florida • Saint Charles, Illinois + 4 more
- Conditions
- Anemia
- Interventions
- Peginesatide, Epoetin alfa
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Azusa, California + 20 more
- Conditions
- Healthy Volunteers
- Interventions
- Teduglutide, Syringe Injection, Pen injector
- Drug · Device
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Respiratory Syncytial Virus
- Interventions
- mRNA-1345, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 0 Years to 40 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 22
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more
- Conditions
- HIV Infections
- Interventions
- Infant Formula
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Day to 17 Days
- Enrollment
- 2,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2005
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
- Conditions
- Progressive Cognitive Decline
- Interventions
- florbetapir F 18
- Drug
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 14 more
- Conditions
- Lung Cancer
- Interventions
- topotecan hydrochloride
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 48 more
- Conditions
- Urinary Incontinence
- Interventions
- Tolterodine ER 4 mg QD, OAB Patient Behavioral Training Material
- Drug · Behavioral
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 48 more